Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198565 | 1.00 | CXCR2 (0.34) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL1768213 | 0.84 | CXCR2 (0.35) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL1924669 | 0.84 | CXCR2 (0.35) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL1768211 | 0.84 | CXCR2 (0.35) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL16584183 | 0.79 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL2797628 | 0.79 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL2598240 | 0.79 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL324715 | 0.76 | POLB (0.38) | CXCR2ALDH1A1L3MBTL1 | |
| SCHEMBL3761384 | 0.76 | CA12 (0.36) | CXCR2CXCR1 | |
| SCHEMBL324716 | 0.76 | POLB (0.38) | CXCR2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140315911-A1 | DIHYDROPTERIDINONES | OSI Pharmaceuticals, LLC | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315911-A1 | DIHYDROPTERIDINONES | DHPS, DHODH, HYPK | CXCR2 1860/4885CXCR1 1524/4885ALDH1A1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.